Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

被引：0
|
作者：
Keiji Tsuji
Masayuki Kurosaki
Jun Itakura
Nami Mori
Shintaro Takaki
Chitomi Hasebe
Takehiro Akahane
Kouji Joko
Hitoshi Yagisawa
Jirou Takezawa
Ryou Nakata
Atsunori Kusakabe
Yuji Kojima
Hiroyuki Kimura
Takashi Tamada
Haruhiko Kobashi
Akeri Mitsuda
Masahiko Kondou
Chikara Ogawa
Yasushi Uchida
Tetsuro Sohda
Ryouichi Narita
Namiki Izumi
机构：
[1] Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital,Department of Gastroenterology
[2] Musashino Red Cross Hospital,Department of Gastroenterology and Hepatology
[3] Japanese Red Cross Asahikawa Hospital,Department of Gastroenterology
[4] Japanese Red Cross Ishinomaki Hospital,Department of Gastroenterology
[5] Matsuyama Red Cross Hospital,Center for Liver
[6] Japanese Red Cross Akita Hospital,Biliary
[7] Japanese Red Cross Haramachi Hospital,Pancreatic Disease
[8] Japanese Red Cross Medical Center,Department of Gastroenterology
[9] Japanese Red Cross Nagoya Daini Hospital,Department of Internal Medicine
[10] Japanese Red Cross Ise Hospital,Department of Gastroenterology
[11] Japanese Red Cross Kyoto Daiichi Hospital,Department of Gastroenterology
[12] Takatsuki Red Cross Hospital,Department of Hepatology
[13] Japanese Red Cross Okayama Hospital,Department of Gastroenterology
[14] Japanese Red Cross Tottori Hospital,Department of Gastroenterology
[15] Japanese Red Cross Otsu Hospital,Department of Gastroenterology
[16] Takamatsu Red Cross Hospital,Department of Gastroenterology
[17] Matsue Red Cross Hospital,Department of Gastroenterology
[18] Japanese Red Cross Fukuoka Hospital,Department of Gastroenterology
[19] Oita Red Cross Hospital,Department of Gastroenterology
来源：
Journal of Gastroenterology | 2018年 / 53卷
关键词：
Chronic hepatitis C; Ledipasvir; Sofosbuvir; Alpha-fetoprotein;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1142 / 1150
页数：8
相关论文
共 50 条
  • [21] Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study
    Serranti, Daniele
    Nebbia, Gabriella
    Cananzi, Mara
    Nicastro, Emanuele
    Di Dato, Fabiola
    Nuti, Federica
    Garazzino, Silvia
    Silvestro, Erika
    Giacomet, Vania
    Forlanini, Federica
    Pinon, Michele
    Calvo, Pier Luigi
    Riva, Silvia
    Dodi, Icilio
    Cangelosi, Antonina Marta
    Antonucci, Roberto
    Ricci, Silvia
    Bartolini, Elisa
    Mastrangelo, Greta
    Trapani, Sandra
    Lenge, Matteo
    Gaio, Paola
    Vajro, Pietro
    Iorio, Raffaele
    D'Antiga, Lorenzo
    Indolfi, Giuseppe
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 72 (01): : 95 - 100
  • [22] Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study
    Tapper, E. B.
    Bacon, B. R.
    Curry, M. P.
    Dieterich, D. T.
    Flamm, S. L.
    Guest, L. E.
    Kowdley, K. V.
    Lee, Y.
    Tsai, N. C.
    Younossi, Z. M.
    Afdhal, N. H.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (01) : 22 - 27
  • [23] Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
    Chiu, Wen-Nan
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Chen, Mei-Yen
    Tung, Shui-Yi
    Wei, Kuo-Liang
    Lu, Chung-Kuang
    Chen, Chien-Hung
    Hu, Tsung-Hui
    Hu, Jin-Hung
    Chen, Wei-Ming
    Chang, Te-Sheng
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 866 - 872
  • [24] The effectiveness and safety of sofosbuvir-ledipasvir for patients with hepatitis C virus genotype 2 infection
    Chen, Po-Yueh
    Yang, Hsin-Yi
    Chou, Chu-Kuang
    Chang, Li-Jen
    Hsu, Ming-Tse
    Tsai, Tsung-Jung
    Fang, Chien-Chung
    Su, Chang-Chao
    Lin, Yu-Ling
    Feng, Yu-Ming
    Chen, Chi-Yi
    ADVANCES IN DIGESTIVE MEDICINE, 2022, 9 (02) : 91 - 97
  • [25] EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
    Yue, Wei
    Liu, Li
    Xiao, An
    Du, Yingrong
    Gao, Jianpeng
    Liu, Min
    Wang, Yilan
    Che, Meng
    Guo, Jiaxiang
    Li, Junyi
    Geng, Jiawei
    HEPATOLOGY, 2021, 74 : 589A - 589A
  • [26] Effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: real-world data from Georgian hepatitis C elimination program
    Tsertsvadze, Tengiz
    Chkhartishvili, Nikoloz
    Abutidze, Akaki
    Sharvadze, Lali
    Kerashvili, Vakhtang
    Butsashvili, Maia
    Zarkua, Jaba
    Gvinjilia, Lia
    Nasrullah, Muaz-Zam
    Gamkrelidze, Amiran
    Kvaratskhelia, Valeri
    Afdhal, Nezam H.
    Arora, Sanjeev
    Zeuzem, Stefan
    Thornton, Karla A.
    Averhoff, Francisco
    HEPATOLOGY, 2017, 66 : 855A - 855A
  • [27] Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program
    Tsertsvadze, T.
    Chkhartishvili, N.
    Abutidze, A.
    Sharvadze, L.
    Kerashvili, V.
    Kamkamidze, G.
    Zakalashvili, M.
    Skaggs, B.
    Gvinjilia, L.
    Shadaker, S.
    Nasrullah, M.
    Gamkrelidze, A.
    Kvaratskhelia, V.
    Zeuzem, S.
    Afdhal, N.
    Arora, S.
    Thornton, K.
    Averhoff, F.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S281 - S282
  • [28] Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection
    Asahina, Yasuhiro
    Itoh, Yoshito
    Ueno, Yoshiyuki
    Matsuzaki, Yasushi
    Takikawa, Yasuhiro
    Yatsuhashi, Hiroshi
    Genda, Takuya
    Ikeda, Fusao
    Matsuda, Takuma
    Dvory-Sobol, Hadas
    Jiang, Deyuan
    Massetto, Benedetta
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Kawada, Norifumi
    Enomoto, Nobuyuki
    LIVER INTERNATIONAL, 2018, 38 (09) : 1552 - 1561
  • [29] Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
    Liou B.-H.
    Sun H.-Y.
    Yang C.-J.
    Syue L.-S.
    Lee Y.-L.
    Tang H.-J.
    Tsai H.-C.
    Lin C.-Y.
    Chen T.-C.
    Lee C.-Y.
    Huang S.-H.
    Liu C.-W.
    Lu P.-L.
    Lin S.-P.
    Wang N.-C.
    Cheng A.
    Ko W.-C.
    Cheng S.-H.
    Hung C.-C.
    Infectious Diseases and Therapy, 2021, 10 (2) : 827 - 838
  • [30] Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
    Tao, Tingting
    Jiang, Xuehua
    Chen, Yuehong
    Song, Yiran
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 55 : 56 - 71
12345